SynthesisBMC pregnancy and childbirth2025
Efficacy of raltegravir in achieving virological suppression at delivery in HIV-positive pregnant women: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe world's first HIV integrase inhibitor, raltegravir (RAL), has been widely used for the treatment of HIV infection over the past 15 years, and continues benefiting people living with HIV (PLWH) today due to its efficient virological suppression and favourable safety profile. However, to date, there have not been any published systematic analyses evaluating the efficacy of RAL in HIV-positive pregnant women. Herein, our study aimed to evaluate the efficacy of raltegravir (RAL) regarding virological suppression at delivery in Human immunodeficiency virus (HIV)-positive pregnant women by systematic review and meta-analysis.
methodsIn this study, we searched PubMed, EMBASE, the Cochrane Library, and Web of Science from inception until January 17th, 2023. Clinical trials and observational studies (cohort studies, case series, case reports) were included. All analyses were performed using R 4.1.1 statistical software with random effects modelling.
resultsTwenty-two studies with 806 HIV-positive pregnant women were included. Pooled analysis indicated that the overall effectiveness rate for achieving virological suppression at delivery is 85% (95% confidence interval [CI]: 79% - 90%). Analysis of secondary outcomes revealed an overall efficacy of 78% (95% CI: 72% - 84%) for those with an HIV RNA load of < 1000 RNA copies/mL at delivery when RAL was initiated from the second trimester onward. Additionally, subgroup analysis showed an overall effectiveness rate of 75% (95% CI: 58% - 87%) for treatment-naïve (n = 29) and 76% (95% CI: 60%-86%) for treatment-experienced patients (n = 38).
conclusionIt concluded that RAL is effective for achieving virological suppression at delivery in HIV-positive pregnant women, and possibly contribute to the prevention of mother-to-child HIV transmission.
trial registrationThis study was registered in PROSPERO, with registration number: CRD42023428508.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.